Patents by Inventor Barbara Costa

Barbara Costa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a combination of Adelmidrol and hyaluronic acid in the treatment of pain caused by osteoarthritis and epithelial dysfunctions
    Patent number: 11491122
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 8, 2022
    Assignee: Epitech Group S.p.A.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • COMPOUNDS WITH A BENZO[A]CARBAZOLE STRUCTURE AND USE THEREOF
    Publication number: 20200299306
    Abstract: Disclosed are compounds of general formula (I), and their use for the treatment and diagnosis of degenerative disorders characterized by high cell proliferation and/or tissue degeneration.
    Type: Application
    Filed: September 4, 2018
    Publication date: September 24, 2020
    Inventors: Armando ROSSELLO, Elisa NUTI, Elisabetta ORLANDINI, Susanna NENCETTI, Claudia MARTINI, Barbara COSTA, Chiara GIACOMELLI, Simona DANIELE
  • Use of Adelmidrol in the Treatment of Epithelial Dysfunctions
    Publication number: 20190224145
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: Epitech Group S.p.A.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
    Publication number: 20190224140
    Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
    Type: Application
    Filed: September 26, 2018
    Publication date: July 25, 2019
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Barbara Costa
  • Use of Adelmidrol in the Treatment of Epithelial Dysfunctions
    Publication number: 20170209395
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Epitech Group S.r.l.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • Use of Adelmidrol in the Treatment of Epithelial Dysfunctions
    Publication number: 20160008301
    Abstract: The described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: July 7, 2015
    Publication date: January 14, 2016
    Applicant: Epitech Group S.r.l.
    Inventors: Maria Federica DELLA VALLE, Francesco DELLA VALLE, Vincenzo DI MARZO, Stefania PETROSINO, Barbara COSTA, Gabriele MARCOLONGO, Daniele GRASSI
  • CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
    Publication number: 20120245224
    Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
    Type: Application
    Filed: June 7, 2012
    Publication date: September 27, 2012
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Barbara Costa
  • Cannabinoids for use in the treatment of neuropathic pain
    Publication number: 20100016418
    Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
    Type: Application
    Filed: June 21, 2007
    Publication date: January 21, 2010
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Barbara Costa